Idiopathic Recurring Angioedema: A Possible Case of Hereditary Angioedema Type III

  • Lara Sales Biermann Médica Residente do Serviço de Dermatologia do Hospital Universitário - Universidade Federal de Sergipe (HU-UFS) , Brasil
  • Isis Vasconcelos Lima Médica Residente do Serviço de Dermatologia do Hospital Universitário - Universidade Federal de Sergipe (HU-UFS) , Brasil
  • Juliana Oliveira Santos Médica Residente do Serviço de Dermatologia do Hospital Universitário - Universidade Federal de Sergipe (HU-UFS), Brasil
  • Pedro Dantas Oliveira Dermatologista Especialista pela Sociedade Brasileira de Dermatologia, Doutor em Medicina e Saúde pela Universidade Federal da Bahia - Brasil, Professor Titular de Dermatologia da Universidade Federal de Sergipe
  • Maite Passos Costa Estudante de Medicina da Universidade Federal de Alagoas, Brasil
  • Katia Aguiar Lima Dermatologista Especialista pela Sociedade Brasileira de Dermatologia, Brasil
Keywords: Hereditary Angioedema Type III, Tranexamic Acid

Abstract

Three types of hereditary angioedema (HAE) have been described within the spectrum of idioptahic nonhistaminergic angioedema. Type I and II related with C1-INH (C1-esterase inhibitor) deficiency is more frequent and type III is rare, occurs mostly in young women, without C1 inhibitor (C1-INH) alterations, and may be associated with mutations in the factor XII gene. Trauma, stress and estrogen may be the precipitants, treatment is still a challenge due to the absence of controlled studies. We present a case of possible type III HF in a young woman, aggravated by the introduction of anti-conception and improvement with its suspension and treatment with tranexamic acid, but without a family history or a factor XII mutation.

Downloads

Download data is not yet available.

References

Ferraro MF ArrudaKL, Maia LS, Moreno AS. Hereditary

angioedema and other forms of bradykinin-mediated

angioedema: update on diagnosis and treatment. Braz J

Allergy Immunol. 2014; 2:6-20.

Valle SR, França AT, Campos R, Grumach AS. Hereditary

angioedema. Rev Bras Alerg Imunopatol. 2010; 33:80-7.

Frank MM. Hereditary angioedema: a current state-of-

-the-art review, VI: novel therapies for hereditary angioedema.

Ann Allergy Asthma Immunol. 2008; 100:S23-9.

Banerji A, Sloane DE, Sheffer AL. Hereditary angioedema:

a current state-of-the-art review, V: attenuated androgens

for the treatment of hereditary angioedema.

Ann Allergy Asthma Immunol. 2008; 100:S19-22.

Bork K, Barnstedt S, Koch P, Traupe H. Hereditary angioedema

with normal C1-inhibitor activity in women.

Lancet. 2000; 356:213-217.

Binkley KE, Davis A 3rd. Clinical, biochemical, and genetic

characterization of a novel estrogen-dependent

inherited form of angioedema. J Allergy Clin Immunol.

; 106:546-50.

Miranda AR, Ue AP, Sabbag DV, Furlani WJ, Souza PK,

Rotta O. Angioedema hereditário tipo III (estrógeno-dependente):

relato de três casos e revisão da literatura.

An Bras Dermatol. 2013; 88:587-93.

Bianchi PG, França AT, Grumach AS. Diretrizes do

diagnóstico e tratamento do angioedema hereditário.

Rev Bras Alerg Imunopatol. 2010; 33:241-52.

Bouillet L. Hereditary angioedema in women. Allergy Asthma

Clin Immunol. 2010; 6:17.

Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson

DA, Horn PT. The humanistic burden of hereditary

angioedema: Impact on health-related quality of

life, productivity, and depression. Allergy Asthma Proc.

; 31:407-14.

Deroux A, Boccon-Gibod I, Fain O, Pralong P, Ollivier

Y, Pagnier A, et al. Hereditary angioedema with normal

C1 inhibitor and factor XII mutation: a series of 57 patients

from the French National Center of Reference for

Angioedema. Clin Exp Immunol. 2016; 185:332-7.

Bowen T, Cicardi M, Bork K, Zuraw B, Frank M, Ritchie

B, et al. Hereditary angioedema: a current state-of-the-

-art review, VII: Canadian Hungarian 2007 International

Consensus Algorithm for the Diagnosis, Therapy, and

Management of Hereditary Angioedema. Ann Allergy

Asthma Immunol. 2008; 100:S30-40.

Andrade, P. Erythema Marginatum-like. Rev Soc Port

Dermatol Venereol. 2016; 74: 413-4.

Germenis A, Speletas M. Genetics of hereditary angioedema

revisited. Clin Rev Allergy Immunol. 2016;

:170-82.

Giavina-Bianchi P, Motta A, Kalil J. Therapeutic agents for

hereditary angioedema. N Engl J Med. 2011; 364:84-6.

Bork K, Gül D, Hardt J, Dewald G. Hereditary angioedema

with normal C1 inhibitor: clinical symptoms and

course. Am J Med. 2007; 120:987-92.

Tallroth GA. Long-term prophylaxis of hereditary angioedema

with a pasteurized C1 inhibitor concentrate.

Int Arch Allergy Immunol. 2010; 154:356-59.

Farkas H, Czaller I, Csuka D, Vas A, Valentin S, Varga

L, et al. The effect of long-term danazol prophylaxis on

liver function in hereditary angioedema in hereditary

angioedema-a longitudinal study. Eur J Clin Pharmacol.

; 66:419-26.

Cicardi M, Banerji A, Bracho F, Malbrán A, Rosenkranz

B, Riedl M, et al. Icatibant, a new bradykinin-receptor

antagonist, in hereditary angioedema. N Engl J Med.

; 363:523-31.

Zuraw BL, Busse PJ, White M, Jacobs J, Lumry W, Baker

J, et al. Nano ltered C1 inhibitor concentrate for treatment

of hereditary angioedema. N Engl J Med. 2010;

:513-22.

Cicardi M, Levy RJ, McNeil DL, Li HH, Sheffer AL, Campion

MM, et al. Ecallantide for the treatment of acute

attacks in hereditary angioedema. N Engl J Med. 2010;

:532-41.

Bygum A, Andersen KE, Mikkelsen CS. Self-administration

of intravenous C1-inhibitor therapy for hereditary

angioedema and associated quality of life benefits. Eur J

Dermatol. 2009; 19:147-51.

Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA.

Dipeptidyl peptidase-IV inhibitor use associated with increased

risk of ACE inhibitor-associated angioedema.

Hypertension. 2009; 54:516-23.

Cugno M, Castelli R, Cicardi M. Angioedema due to

acquired C1- inhibitor de ciency: a bridging condition

between autoimmunity and lymphoproliferation. Autoimmun

Rev. 2008; 8:156-9.

Birjmohun RS, Kees Hovingh G, Stroes ES, Hofstra JJ,

Dallinga- Thie GM, Meijers JC, et al. Effects of short-

-term and long-term danazol treatment on lipoproteins,

coagulation, and progression of atherosclerosis: two clinical

trials in healthy volunteers and patients with hereditary

angioedema. Clin Ther. 2008; 12:2314-23.

Aygören-Pürsün E, Magerl M, Graff J, Martinez-Saguer

I, Kreuz W, Longhurst H, et al. Prophylaxis of hereditary

angioedema attacks: A randomized trial of oral plasma

kallikrein inhibition with avoralstat. J Allergy Clin Immunol.

; 138:934-6.

Bowen T, Cicardi M, Farkas H, Bork K, Longhurst HJ,

Zuraw B, et al. 2010 International consensus algorithm

for the diagnosis, therapy and management of hereditary

angioedema. Allergy Asthma Clin Immunol. 2010;

:24.

Published
2018-01-26
How to Cite
Sales Biermann, L., Vasconcelos Lima, I., Oliveira Santos, J., Dantas Oliveira, P., Passos Costa, M., & Aguiar Lima, K. (2018). Idiopathic Recurring Angioedema: A Possible Case of Hereditary Angioedema Type III. Journal of the Portuguese Society of Dermatology and Venereology, 75(4), 413-416. https://doi.org/10.29021/spdv.75.4.689
Section
Case Reports